MEKiAUTO: Phase 1/2 open-label study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the AUTOphagy inhibitor, hydroxychloroquine in KRAS-mutated advanced malignancies.
Combination Therapy in KRAS-mutated Advanced Malignancies (MEKiAUTO)
Sponsor: Genentech
Enrolling: Male and Female Patients
IRB Number: AAAS4165
U.S. Govt. ID: NCT04214418
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine how safe and effective the combination of atezolizumab, cobimetinib, and hydroxychloroquine is at treating KRAS-mutated advanced malignancies, and also to determine the maximum dose of this combination of drugs that can be tolerated by patients. This combination is thought to work by increasing the body's ability to attack tumors through its immune system. Cancers include colon and rectal, lung cancer, pancreatic cancer, and stomach cancer.
This study is closed
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Do you have advanced cancer, such as pancreatic, colorectal, or non-small cell lung cancer, for which there is no treatment? Yes No
Are you 18 years of age or older? Yes No
Are you willing to use birth control for the duration of the study? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE